

#### PRECISION ONCOLOGY: PTX-100 AND PTX-200

FROM ROBUST SCIENCE TO EVIDENCED-BASED CANCER TREATMENT

Professor Saïd Sebti Chief Scientific Officer Prescient Therapeutics Limited (ASX: PTX) Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forwardlooking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this presentation. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.


Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favorable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.



#### **INTRODUCING SAID SEBTI, CSO OF PRESCIENT**





- Chief Scientific Officer, Prescient Therapeutics
- Professor and Chair, Drug Discovery Department, Moffitt Cancer Center in Tampa, FL
  - » 3rd largest cancer centre in the US
  - » 800 research scientists, postdocs, graduate students and support staff
- Co-inventor of PTX-100 & PTX-200
- Named among Top 20 Translational Researchers in the world by Nature Publishing Group




g nature publishing group



3 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE

# COMPANY OVERVIEW







#### **INVESTMENT HIGHLIGHTS**

#### 2 DRUGS » IMMINENT CATALYSTS » FUNDING IN PLACE » UNDISCOVERED VALUE

- Multiple shots on goal with novel targeted (personalized) cancer therapies
- One of deepest clinical pipelines on the ASX
- Funded through to value-accretive catalysts, with a fantastic share register
- Great scientific and clinical team with a proven record of success
- Transformative opportunity in Ras/Rho mutant cancers
- Following in the footsteps of US targeted therapy companies that have enjoyed spectacular success
- Multiple catalysts this year
- Encouraging Ph1b breast cancer results




#### **CORPORATE SNAPSHOT**

#### **KEY METRICS**

ASX Ticker	PTX
Total Issued Capital	211.3 M shares
Options	57.8 M
Share Price <sup>1</sup>	A\$0.12 (US\$0.09)

Market Capitalisation <sup>1</sup>	A\$25 M (US\$19.5 M)
Cash Position <sup>2</sup>	A\$6.0 M (US\$4.7 M)
Top 20 Own	52%
6 month turnover <sup>3</sup>	22.7 M shares; A\$1.6 M (US\$1.3 M)









#### DEEP, CLINICAL STAGE PRODUCT PIPELINE

- PTX-200 currently in three clinical trials
- Advancing PTX-100 in basket studies of Ras and Rho mutant cancers a transformative opportunity






Akt, Rho & Ras are growth molecules – when they are stuck "on", they send **constant signals** to the cancer cell to **grow** and **cause resistance** to treatment



**Prescient** Therapeutics

PTX's drugs block the Akt, Rho & Ras growth pathways, switching the **growth signals off** and **causing the cancer cell to die** 

#### **TURNING OFF TUMOUR MASTER SWITCHES**




# PRECISION ONCOLOGY EXPLAINED



11 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE

### **PRECISION ONCOLOGY INTRODUCTION**

- Treatment takes into account individual tumor variability
- Doctors predict more accurately which anti-cancer drug will work in which groups of people
- Not a one-size-fits-all approach where treatment is for all patients, with no attention to differences between individuals
- This practice has precedent: For example, in blood transfusion the donor's blood type is matched to the recipient (no one is given blood from a randomly selected donor).




• The Precision Medicine industry was valued at **US\$39B in 2015**, and is expected to reach **US\$98B by 2023**, expanding at a rate of 12.3%



### WHY PRECISION ONCOLOGY?

 Many types of cancers (breast, ovarian, lung, colon etc); within same cancer type, cancer patients' tumors can differ from one another: Tumors arise from different cancer-causing mutations and proteins.




• Precision Oncology tailors the treatment of a cancer patient with specific drugs that target the specific cancer-causing mutations or proteins that define the blueprint of that patients' individual tumor.



### STEPS INVOLVED IN PRECISION ONCOLOGY


1. Each cancer patient tumor is first analyzed for mutations & other molecular biomarkers (i.e. DNA/RNA sequencing; Phosphorylation)



This way, only patients that are more likely to respond are treated with the **right drug** for the **right patient** with the **right tumor profile** 



This **precise**, **targeted** personalized therapy is a **more effective** way of treating cancer patients.





SUCCESS **STORIES IN** PRECISION ONCOLOGY



### **EXAMPLES OF PRECISION ONCOLOGY APPROACHES**

Disease	Target	Drug	Status
Chronic Myeloid Leukemia	<b>Bcr-Abl</b> (95% of patients)	Gleevec 🔥 NOVARTIS	Gleevec has increased 5-year survival rate for CML from 31% to 90% (1990s-2012)
Acute Myeloid Leukemia	FLT3 (25% of AML patients)	Gilteritinib Astellas	NDA filed for R/R FLT3-positive AML
Acute Myeloid Leukemia	IDH2 (8% of AML patients)	Enasidenib	Received FDA approval in 2017 for R/R AML with IDH2 mutations
Many cancer types	<b>TRK fusions</b> (various %s)		NDA filed for cancers with TRK fusion
Many cancer types	High <b>p-Akt</b> (various %s)	PTX-200 Prescient	<b>In development</b> for cancers with <b>high p-Akt</b> levels (regardless of the genetic defect that causes high p-Akt)
Various Lymphomas	<b>RhoA</b> mutations (up to 70%)	PTX-100 Prescient	In development for cancers with RhoA mutations
Gastric and pancreatic cancers	<b>KRas</b> mutations (up to 95%)	PTX-100 Prescient	In development for cancers with KRas mutations



17 targeted therapies yielding a deep clinical pipeline

#### **TARGETED THERAPIES CASE STUDY #1: LOXO**



 Loxo Oncology (NASDAQ: LOXO); US\$3.9B market cap



- TRK inhibitor targeting cancers with TRK fusions
- Deal for LOXO-101 and LOXO-195
- In mid-stage clinical trials ORR 75%
- Bayer deal US\$400m upfront
- Loxo could earn up to US\$1.55 Billion
- Bayer and Loxo co-promote in US; Bayer solo RoW
- 923% return in 4 years





#### **TARGETED THERAPIES CASE STUDY #2: BLUEPRINT**



- Blueprint Medicines (NASDAQ: BPMC)
- Target therapies for cancer based on genomically defined diseases (abnormal kinase activation)
- 4x Phase 1 drugs
- 3 x discovery programs
- IPO April 2015: Valuation: US\$398M; \$16/share
- Today: Valuation: US\$3.8 B; \$78/share
- 342% return in <3 years






#### PRESCIENT FOLLOWING THE SAME DEVELOPMENT PATH

- Prescient Therapeutics (ASX: PTX); market cap \$22M
- Target therapies for cancer
- Hyper pAkt PTX-200
  - » Orphan drug designation in AML
- Ras/Rho mutations PTX-100
  - » Including ultra-orphan RhoA mutant lymphomas
- A step behind some US peers, but treading the same path!








20 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE

#### PTX-100 AND PTX-200 PRECISION ONCOLOGY





PTX-200

NOVEL AKT INHIBITION

AML Breast cancer Ovarian cancer




#### **PTX-200 PRECISION ONCOLOGY VALIDATION**

#### • PTX-200 stops the growth of only tumors that harbor high p-Akt levels

- » PTX-200: Inhibitor of AKT hyper-activationcommon in 50-70% of breast, ovarian, colorectal, prostate, pancreatic and Leukemia.
- » Activated AKT causes chemotherapy resistance
- » PTX-200 "switches off" pathway overcomes chemotherapy resistance and causes cancer cells to die


- In addition to high P-Akt levels, other biomarkers that may predict response to PTX-200 are:
  - » Akt mutation (E17K)
  - » High levels of the ZNF217







#### **HER2 - BREAST CANCER OVERVIEW**





- » AKT IS ADVERSE PROGNOSTIC FACTOR
- » CORRELATED WITH WORSE DISEASE-FREE SURVIVAL
- » DRIVES RESISTANCE TO ENDOCRINE THERAPY



PTX'S NICHE: NEOADJUVANT TARGETED THERAPY FOR HER2- DISEASE



#### PHASE 1B BREAST CANCER TRIAL SUCCESSFULLY COMPLETED; NOW IN PHASE 2

- PTX-200 in combination with paclitaxel, followed by AC (doxorubicin & cyclophosphamide)
- Patients with metastatic and locally advanced HER2- breast cancer
- 28 patients dosed; 12 in expansion cohort at 35 mg/m<sup>2</sup>
- 5 patients from Phase 1b qualifying for Phase 2 analysis
- Phase 2 trial currently underway in locally advanced breast cancer













#### WHAT DOES SUCCESS LOOK LIKE FOR THIS DISEASE?

- For women with locally advanced ER+, HER2 negative breast cancer, typical expectations are:
  - » Complete response (complete eradication) of 16% (11-22%)
  - » Overall response rate of 25%

HORTOBAGYI, G. ET AL: J CLIN ONCOL 23:5983-5992: 2005


 A meaningful improvement on these response rates would be seen as very encouraging

• Whilst Prescient is not measuring PFS in this study, pCR is recognised by the FDA as an endpoint to accelerated approval



#### PHASE 1B EFFICACY RESULTS VERY ENCOURAGING

- 10 patients evaluable for efficacy:
  - » 2 complete responses (both in ER+)
  - » Overall response rate of 50%
  - » In ER+ disease, ORR (pCR+ PR) was 75%
- Small numbers, but very encouraging efficacy results, particularly in difficult to treat ER+ and locally advanced disease
- 5 patients from Phase 1b qualifying for Phase 2 analysis



metastatic & locally advanced patients			
	ER+	Triple negative	Tota
pCR/CR	2	0	2
PR	1	2	3
SD	1	2	3
PD	0	2	2
ORR	75%	33%	50%

Matastatia 8 Jacolly advanced patients

Locally advanced patients					
	ER+	Triple negative	Total		
pCR/CR	2	0	2		
PR	1	2	3		
SD	0	0	0		
PD	0	0	0		
ORR	60%	40%	100%		




7 PCR=PATHOLOGICAL COMPLETE RESPONSE; CR=COMPLETE RESPONSE; PR=PARTIAL RESPONSE;; SD=STABLE DISEASE; PD=PROGRESSIVE DISEASE; ORR=OVERALL RESPONSE RATE (=PCR/CR + PR)

### AML: MUTATIONAL COMPLEXITY NEEDS PRECISION APPROACH

 Regardless of the mutational complexity of AML, 72% of AML patients have high p-Akt

 PTX-200 has the potential to complement other targeted therapies, and capture what they cannot





28 KRONKE, J; ET AL. BLOOD 2013; 122:100-108 DAVER N, ET AL. AM J HEMATOL. 2016; 91:131-145 PATEL, ET AL. NEJM 2012; 366:1079 BRANDTS, ET AL. CANCER RES 2005; 65:9643

#### PHASE 1B AML TRIAL UNDERWAY

- Phase 1 results with PTX-200 (monotherapy) very encouraging
- Now PTX-200 + cytarabine in refractory or relapsed acute leukemia
- World renowned expert Professor Jeff Lancet at Moffitt Cancer Center leading the trial
- Yale Cancer Center and Kansas University Medical Center also participating in trial
- Due to complete Phase 1b around middle of 2018



Jeffrey E Lancet, M.D. Principal Investigator





#### PHASE 1B OVARIAN CANCER TRIAL

- Significant need for new products to treat platinum-resistant ovarian cancer
- Testing PTX-200 plus carboplatin in patients with platinum resistant ovarian cancer
- PTX-200 already proven overcome cisplatin resistance and synergize with cisplatin in pre-clinical studies
- Phase 1b underway
- Currently recruiting at H. Lee Moffitt Cancer Center









# PTX-100

#### PHASE 1 IN SOLID TUMORS COMPLETED

## NOW PURSUING A TRANSFORMATIVE OPPORTUNITY IN RAS AND RHO MUTANT CANCERS




### **PTX-100 PRECISION ONCOLOGY**

- PTX-100 is predicted to inhibit tumors that harbor mutant RhoA and mutant KRas
  - » PTX-100: 1st in class/man inhibitor of Ras (mutated in 30% of human cancers) and Rho (mutated in up to 70% of AITL) pathways
  - » PTX-100 "switches off" these pathways by targeting GGT-1, enzyme
  - » PTX-100 completed Phase 1: Safe and patients achieved stable disease
  - » Soon to enter Pilot and Phase II
- In addition to high mutant RhoA and mutant KRas, other biomarkers that may predict response to PTX-200 are:
  - » p27Kip
  - » PTEN
  - » RalA/B



#### PTX-100 THE MOST ADVANCED DRUG TARGETING RHOA

- Only RhoA inhibitor in the clinic
- Phase 1 trial in solid tumours completed
- PTX-100 has a unique position in RhoA mutant lymphomas












### A QUICKER, CHEAPER ROUTE TO MARKET







 $35_{\substack{\mathsf{PIPELINE}}}$ 

#### **CASE STUDY : FOLOTYN**

- Developed by Allos, acquired by Spectrum Pharmaceuticals
- For relapsed & refractory Peripheral T-cell lymphoma
  - » 5,600 cases/year in US
- Approved on overall response rate of 27%
- Currently priced at US\$450,540 per patient, per year







#### 12 MONTHS GOALS AS SET OUT AT 2017 AGM

- Removal of clinical hold on PTX-200 breast cancer trial
- Final data on the Phase 1b PTX-200 breast cancer trial
- Continuing Phase 2 PTX-200 breast cancer trial
- Manufacturing run of PTX-100 and additional inventory of PTX-200
- Pre-clinical work in PTX-100 in RhoA mutant cancers
- Completion of PTX-200 AML Phase 1b trial
- Completion of PTX-200 ovarian cancer Phase 1b trial
- Re-entering the clinic with PTX-100
- Continuing to build awareness among investors, clinicians and corporates





**<sup>37</sup>** TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE

#### **INVESTMENT SUMMARY**



- Multiple shots on goal with novel targeted (precision) cancer therapies
- Robust body of science underpinning programs
- Great scientific and clinical team with a proven record of success
- Transformative opportunity in Ras/Rho mutant cancers
- Following in the footsteps of US targeted therapy companies that have enjoyed spectacular success
- Multiple catalysts this year
- Encouraging efficacy signal in Ph1b breast cancer



**38** TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE



#### CONTACT

Steven Yatomi-Clarke CEO & Managing Director Prescient Therapeutics Limited

- e: steven@ptxtherapeutics.com
- *t:* +61 417 601 440
- w: ptxtherapeutics.com

